CSL Behring is the company that sells Vivablobin which is the blood product used in the vast majority of REPR pump applications. The segment of CSL's business that sells Vivaglobin had 32% growth in the second half of 2008 and they state that Vivaglobin "attracted significant patient growth." This bodes quite well for REPR. Here is the full text of the corresponding portion of their report:
"Immunoglobulins grew 32% in US dollar terms with good growth in specialty products Cytogam® and Rhophylac®. Vivaglobin® (subcutaneous Immunoglobulin), a product which provides the convenience of immunoglobulin self administration, attracted significant patient growth. Global IVIG sales growth benefited equally from growth in price, volume and product mix as demand moves in favour of liquid presentations over lyophilised. The Critical Care segment grew 25% in US dollar terms underpinned by price and volume growth of albumin. Specialty products, particularly Haemocomplettan® P, Beriplex® P/N and Berinert® P, also made a strong contribution."
CSL, the makers of Vivaglobin which is turn has been key for REPR's sales of their Freedom60 pump which in turn is driving REPR's sales & net income, is being pushed by CSL to be administered at home, according to this December 11, 2008 PR:
Market Data 
Markets 
AI
